Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 219
Filter
2.
Article in Chinese | WPRIM | ID: wpr-880431

ABSTRACT

In this study, cytometric beads array(CBA) was used to determine the immunoglobulin content in humoral immunity evaluation of biomedical materials. The bovine-derived acellular dermal matrix was selected as a test sample and implanted into Balb/C mice subcutaneously to 4 weeks according to the high, medium and low dose groups. Four weeks later, IgG1, IgG2a, IgG2b, IgG3, IgA, and IgM were measured by CBA. The data of the test group and the control group were analyzed statistically. The results showed that compared with the negative control group, there was no significant difference in the IgG3, IgA content in the positive control group, while the IgG1, IgG2a, IgG2b, and IgM contents were significantly higher than the negative control group; no significant differences were seen in the sample groups. The results show that the method is suitable for analysis of immunoglobulin content in humoral immunity evaluation of biomedical materials.


Subject(s)
Animals , Cattle , Immunity, Humoral , Immunoglobulin A , Immunoglobulin G , Immunoglobulin M , Mice , Mice, Inbred BALB C , Mice, Inbred CBA
3.
Arq. bras. med. vet. zootec. (Online) ; 72(3): 915-920, May-June, 2020. tab, graf
Article in English | LILACS, VETINDEX | ID: biblio-1129595

ABSTRACT

Nabumetone is used to reduce the pain and inflammation in rheumatoid arthritis. In the current study, immunomodulatory effect of Nabumetone is investigated in mice. The control group was administered normal saline orally as placebo. Nabumetone was administered orally via gavage in two treatment groups at 14mg/kg.b.w. doses and 28mg/kgb.w., respectively. Haemagglutination (HA) assay, Jerne hemolytic plaque and mice lethality assays were applied. In HA assay, the titer was significantly decreased in Nabumetone treatment groups (P< 0.001). In Jerne hemolytic plaque formation assay, there was a significant reduction (P< 0.001) in number of plaques in Nabumetone treated groups when compared with control. In mice lethality assay, there was a significant difference in mortality ratio of mice in control and Nabumetone treated groups (P< 0.001). Therefore, it is concluded that Nabumetone suppresses the humoral immune response in mice.(AU)


A nabumetona é usada na redução da dor e inflamação da artrite reumática. No presente estudo, o efeito imunomodulador é investigado em camundongos. O grupo de controle recebeu solução salina via oral como placebo. Nabumetona foi administrada oralmente via gavagem em dois grupos de tratamentos com doses de 14mg/kg.b.w. e 28mg/kgb.w., respectivamente. Foram realizados ensaios de hemaglutinação (HA), placa hemolítica de Jerne e letalidade dos camundongos. No ensaio HA, o grau foi significativamente menor nos grupos de tratamento com nabumetoma (P< 0.001). No ensaio de formação de placa hemolítica de Jerne houve redução significativa (P< 0.001) no número de placas em grupos tratados com nabumetoma comparado ao controle. No ensaio de letalidade dos camundongos houve diferença significativa no grau de mortalidade de camundongos no grupo de controle e grupos tratados com nabumetoma (P< 0.001). Portanto, conclui-se que a Nabumetoma suprime a resposta imune humoral em camundongos.(AU)


Subject(s)
Animals , Mice , Immunity, Humoral/drug effects , Nabumetone/administration & dosage , Immunologic Factors/analysis , Arthritis, Rheumatoid/veterinary , Saline Solution , Hemagglutination
4.
Arq. bras. med. vet. zootec. (Online) ; 72(2): 362-370, Mar./Apr. 2020. ilus, graf
Article in Portuguese | LILACS, VETINDEX | ID: biblio-1128206

ABSTRACT

Objetivou-se avaliar o efeito dos anticorpos (ACs) maternos sobre resposta imune humoral induzida pela vacinação em bezerros Holandeses. Bezerros foram distribuídos aleatoriamente em quatro grupos: G1 - vacinados no D14 e D44 (n=6); G2 - vacinados no D90 e D120 (n=5); G3 - vacinados no D180 e D210 (n=8); controle: não vacinado (n=5). Utilizaram-se 5mL de vacina comercial (Cattle Master Gold FP5+L5® - Zoetis, Brasil), por via subcutânea. Foi realizada vírus neutralização (VN) no momento da vacinação, booster e 30 dias após a revacinação. Não foram observadas diferenças entre controle e G1 ou G2 para a frequência de soropositivos ou títulos de ACs contra os vírus respiratórios (P≥0,05). G3 apresentou maior produção de ACs em relação ao controle para BoHV-1 (P<0,01), BRSV (P<0,01) e BPIV-3 (P=0,02) após o booster (D240). A análise no tempo também demonstrou aumento nos títulos de ACs no G3 (P≤0,05). O perfil clínico revelou broncopneumonia apenas no grupo controle (n=4/5) entre 80-135 dias de vida. A imunidade colostral e a vacinal apresentaram perfis inversamente proporcionais, com maior produção de ACs aos seis meses de idade. Devido à precocidade da doença respiratória, estudos complementares são necessários para esclarecer o papel da resposta imune celular na vacinação diante dos ACs maternos.(AU)


This research aimed to evaluate the effect of colostral antibodies (ABs) on the humoral immune response induced by vaccination in Holstein calves. Twenty-four calves were randomly assigned into four groups: G1 - vaccinated on D14 and D44 (n= 6); G2 - on D90 and D120 (n= 5); G3 - on D180 and D210 (n= 8); Control: unvaccinated (n= 5). Commercial vaccine (Cattle Master Gold FP5+L5® - Zoetis, Brazil) was administered subcutaneously (5mL). Virus neutralization test (VN) was performed at the time of vaccination, booster and 30 days after booster to determine AB titers. No differences were observed between control and G1 or G2 for seropositive frequencies and ABs titers (P≥ 0.05). G3 showed higher AB production than control for BoHV-1 (P< 0.01), BRSV (P< 0.01) and BPIV-3 (P= 0.02) after booster (D240). Overtime analysis also exhibited increase in AB titers in G3 (P≤ 0,05). Bronchopneumonia was identified in the control group (n= 4/5) between 80-135 days of life. The colostral and vaccinal immunity presented inversely proportional profiles, with higher production of ABs at 6 months of age. Due to the precocity of respiratory disease further studies are required to clarify the role of cellular immune response to vaccination in face of maternal ABs.(AU)


Subject(s)
Animals , Cattle , Bronchopneumonia/veterinary , Vaccination , Immunity, Humoral , Immunity, Maternally-Acquired , Respiratory Tract Diseases/veterinary
5.
Rev. chil. infectol ; 37(2): 138-146, abr. 2020. tab, graf
Article in Spanish | LILACS | ID: biblio-1126100

ABSTRACT

Resumen Introducción: Los pacientes con leucemia linfoblástica aguda (LLA) tienen alto riesgo de influenza grave y la vacunación es altamente recomendada. La inmunogenicidad y efectividad de la vacuna es menor comparada a los sujetos sanos. Objetivo: Evaluar la respuesta inmune inducida por vacuna anti-influenza en niños con LLA y observar su efectividad. Métodos: Se reclutaron niños con LLA en terapia de mantención y niños sanos. Se tomaron muestras de sangre el día de la vacuna (D0) y al día 28 (D28), y se realizó test de inhibición de hemaglutinación (IHA) contra H1N1. Los pacientes fueron seguidos por un año, registrando datos clínicos y episodios de influenza. Resultados: Se incluyeron 34 niños con LLA y 9 niños sanos. Respecto al IHA en D28, 12/34 pacientes y 5/8 niños sanos presentaron títulos ≥ 1/40, resultando una tasa de seroprotección de 35 y 63%, respectivamente. Los niños seroprotegidos eran significativamente mayores. Durante el seguimiento, sólo tres pacientes, no seroprotegidos, presentaron infección por influenza, ninguno requirió oxigeno o cuidados intensivos. Discusión: Los niños con LLA alcanzaron una tasa seroprotección más baja que la observada en niños sanos. Sin embargo, ninguno de los niños seroprotegidos presentó infección por influenza, reforzando la recomendación de vacunación anual.


Abstract Background: Patients with acute lymphoblastic leukemia (ALL) have high risk of severe influenza infection and vaccination is highly recommended. The immunogenicity and effectiveness of vaccination are lower than in healthy people. Aim: To evaluate the immune response induced by influenza vaccine in children with ALL and observe effectiveness. Method: Children with ALL in maintenance phase and healthy children were recruited. Blood samples were taken at vaccination day (D0) and at day 28 (D28). Humoral response was evaluated by hemaglutination inhibition test (HAI) against H1N1. Patients were followed up for one year, clinical data and influenza episodes were recorded. Results: 34 children with ALL and 9 healthy children were included. Concerning HAI on D28, 12/34 patients and 5/8 healthy children had titers ≥ 1/40, with seroprotection rates of 35 and 63% respectively. Seroprotected children were older than non-seroprotected ones. During follow-up, only 3 patients non seroprotected, presented influenza infection, without oxygen supplementation or critical care support. Discussion: Children with ALL had a lower seroprotection rate than healthy children. Nevertheless, none of the seroprotected children presented influenza infection, reinforcing the annual vaccination recommendation.


Subject(s)
Humans , Child , Influenza Vaccines , Influenza, Human , Precursor Cell Lymphoblastic Leukemia-Lymphoma , Vaccination , Influenza A Virus, H1N1 Subtype , Immunity, Humoral , Antibodies, Viral
6.
Int. j. odontostomatol. (Print) ; 14(3): 331-337, 2020. graf
Article in Spanish | LILACS | ID: biblio-1114902

ABSTRACT

A fines de diciembre de 2019, un nuevo coronavirus (SARS-CoV-2) fue identificado como el agente causal de una nueva enfermedad respiratoria llamada COVID-19 por la OMS. Sus síntomas incluyen fiebre, tos seca y dificultad respiratoria. Estos síntomas en general son leves, aunque, pueden ser fatales en adultos mayores y pacientes con comorbilidades. Se realizó búsqueda bibliográfica en Pubmed y Clinical Key donde se seleccionaron 22 artículos de acuerdo con los criterios de inclusión. SARS-CoV-2 pertenece al género de los Betacoronavirus y tiene similitudes genómicas con SARS-CoV y MERS-CoV. El virión de SARS-CoV-2 consta de una nucleocápside y de una envoltura externa compuesta por proteínas estructurales principales y accesorias. Su material genético consiste en una cadena de RNA monocatenario de polaridad positiva, en el que, se codifican proteínas importantes para su transcripción y replicación. El mecanismo de infección de SARS-CoV-2 comienza con la unión del virión a un receptor (ACE2) de la célula huésped y su posterior entrada por endocitosis. El genoma RNA viral se libera al citoplasma donde se transcriben y se traducen las proteínas necesarias para la producción de las proteínas estructurales y para la replicación de su material genético. Posteriormente, el RNA replicado se asocia con la nucleocápside y se ensambla junto con las proteínas estructurales para conformar las partículas víricas que serán liberadas de la célula infectada. El sistema inmune hace frente a la infección viral mediante el reconocimiento de patrones moleculares asociados a patógenos (PAMPs) por parte de la inmunidad innata y por la acción de los linfocitos T y B por parte de la inmunidad humoral. El conocimiento de las bases genéticas y moleculares de SARS-CoV-2 permite visualizar la posibilidad de establecer tratamientos farmacológicos o desarrollo de vacunas para controlar y disminuir los efectos patogénicos de la enfermedad.


In late December 2019, a new coronavirus (SARS-CoV-2) was identified as a causative agent of a new respiratory disease called COVID-19 by WHO. Its symptoms include fever, dry cough, and shortness of breath. Generally, these symptoms are mild, although, can be fatal in older adults and patients with comorbidities. A bibliographic search was carried out in Pubmed and Clinical Key. 22 articles were selected according to inclusion criteria. SARS-CoV-2 belongs to the genus of Betacoronaviruses and has genomic similarities to SARS-CoV and MERS-CoV. SARS-CoV-2 virion is made up of a nucleocapsid and external envelope composed of main structural and accesory proteins. Its genetic is a positive sense single stranded RNA in which important proteins are encoded for their transcription and replication. The mechanism of SARS-CoV-2 infection begins with the binding of the virion to (ACE2) receptor of the host cell and subsequent entry by endocytosis. This RNA genome is released into cytoplasm and the necessary proteins for the production of structural proteins and the replication of genetic material are transcribed and translated. Then, the replicated RNA associates with the nucleocapsid and assembles together with the structural proteins to form the viral particles that will be released from the infected cell. The immune system faces viral infection through the recognition of molecular patterns associated with pathogens (PAMPs) by innate immunity and the action of T cells and B cells by humoral immunity. Knowledge of the genetic and molecular basis of SARS-CoV-2 allows us to visualize the possibility of establishing pharmacological or vaccine treatments to control and reduce the pathogenic effects of the disease.


Subject(s)
Humans , Pneumonia, Viral/transmission , Coronavirus Infections/transmission , Pandemics , Betacoronavirus/genetics , Betacoronavirus/pathogenicity , Pneumonia, Viral/genetics , Pneumonia, Viral/immunology , Coronavirus Infections/genetics , Coronavirus Infections/immunology , Immunity, Humoral , Betacoronavirus/physiology , Immunity, Innate
7.
Rev. bras. parasitol. vet ; 28(4): 533-547, Oct.-Dec. 2019. tab, graf
Article in English | LILACS | ID: biblio-1057985

ABSTRACT

Abstract Fish immune systems have become the subject of several studies due to the growing development of aquaculture and fisheries, and the demand for healthy produce for human consumption. Among the parasites responsible for diseases in fish farming, helminths stand out because they cause infections in farmed fish and decrease food conversion, zootechnical performance and meat quality. In the present review, the components that participate in the innate and adaptive immune responses of teleost fish that have so far been described are presented in order to summarize the defenses that these hosts have recourse to, in combating different groups of helminth parasites.


Resumo O sistema imune dos peixes tem se tornado alvo de muitas pesquisas devido ao crescente desenvolvimento da aquicultura e da pesca, assim como a exigência de obtenção de animais saudáveis para o consumo humano. Dentre os parasitos responsáveis pelas enfermidades na piscicultura, os helmintos destacam-se por causarem infecções nos peixes cultivados e por ocasionarem diminuição da conversão alimentar, do desempenho zootécnico e da qualidade da carne. Nesta revisão, apresentaremos os componentes que participam das respostas imunes inata e adaptativa dos peixes teleósteos já descritos, a fim de sintetizar à quais defesas o hospedeiro recorre frente aos diferentes grupos de parasitos.


Subject(s)
Animals , Immunity, Humoral , Fish Diseases/parasitology , Fishes/parasitology , Helminthiasis, Animal/immunology , Host-Parasite Interactions/immunology , Fish Diseases/immunology , Fishes/immunology , Helminthiasis, Animal/parasitology
8.
Article in English | WPRIM | ID: wpr-719488

ABSTRACT

PURPOSE: Respiratory syncytial virus (RSV) can cause serious respiratory illnesses such as pneumonia, asthma, and bronchiolitis in infants and elderly or immunocompromised individuals. An RSV vaccine has yet to be developed; only prophylactic anti-RSV antibody is commercially available. So, we investigated whether our vaccine candidate is able to induce type 1 CD4+ T helper (Th1), CD8+ T-cell responses, and protective immunity without vaccine-enhanced disease (VED) against RSV. MATERIALS AND METHODS: We used RSV G protein fragment (Gcf A) with recombinant baculovirus capable of expressing the RSV M2 protein (Bac M2) as a vaccine candidate, and injected this vaccine (Gcf A/Bac M2) intramuscularly, and challenged with RSV intranasally into mice. Enzyme-linked immunosorbent assay, flow cytometry, plaque assay, and weight measurement were performed to confirm humoral immunity, cellular immunity, and protective immunity. RESULTS: The Gcf A/Bac M2 formulation induced a stronger IgG response to Gcf A than Gcf A inoculation alone, and the ratio of IgG1/IgG2a indicated that the responses shifted predominantly to Th1. In addition, both RSV G-specific Th1 responses and RSV M2-specific CD8+ T-cell responses were induced, and G protein-associated eosinophilic infiltration was suppressed compared to the control group. Moreover, the Gcf A/Bac M2 group showed effective protection after an RSV challenge. CONCLUSION: Bac M2 could serve as a vaccine with intrinsic adjuvant activity, and the Gcf A/Bac M2 shows promise as a vaccine candidate for inducing protective immunity without inciting VED.


Subject(s)
Aged , Animals , Asthma , Baculoviridae , Bronchiolitis , Enzyme-Linked Immunosorbent Assay , Eosinophils , Flow Cytometry , GTP-Binding Proteins , Humans , Immunity, Cellular , Immunity, Humoral , Immunoglobulin G , Infant , Mice , Pneumonia , Respiratory Syncytial Viruses , T-Lymphocytes
9.
Article in English | WPRIM | ID: wpr-764033

ABSTRACT

The present study aimed at evaluating serum immunoglobulin G (IgG) avidity to Porphyromonas gingivalis in elderly patients with mild and severe chronic periodontitis. The avidity of antibodies against P. gingivalis present in the sera of 18 patients with mild chronic periodontitis and 18 patients with severe chronic periodontitis was evaluated using an ammonium thiocyanate-dissociated enzyme-linked immunosorbent assay (ELISA). The results showed that the mean absorbance value in serum IgG antibody titers was significantly higher in the severe chronic periodontitis group than in the mild chronic periodontitis group (198 ± 35 ELISA unit [EU] vs. 142 ± 32 EU, p < 0.01). However, there was no significant difference between the two groups in antibody avidity (65 ± 57 EU vs. 54 ± 27 EU). These findings suggest that humoral immune responses to P. gingivalis between mild and severe chronic periodontitis in elderly patients are characterized by the differences in the quantity rather than the quality of the antibodies.


Subject(s)
Aged , Ammonium Compounds , Antibodies , Antibody Affinity , Chronic Periodontitis , Enzyme-Linked Immunosorbent Assay , Geriatrics , Humans , Immunity, Humoral , Immunoglobulin G , Immunoglobulins , Porphyromonas gingivalis , Porphyromonas
10.
Immune Network ; : e35-2019.
Article in English | WPRIM | ID: wpr-764025

ABSTRACT

Curcumin is a natural product extracted from Curcuma longa. It has been reported as a potent antioxidant and anti-inflammatory compound. Previous studies have demonstrated that curcumin suppresses pro-inflammatory cytokine production via inhibition of NF-κB in macrophages. However, its role in adaptive immune cells such as T cells, in vivo, has not clearly been elucidated. Here, we examined the effects of curcumin in T follicular helper (T(FH)) cells and on Ab production during NP-ovalbumin immunization in mice. The results revealed that curcumin administered daily significantly increased CXCR5⁺B-cell lymphoma 6⁺ T(FH) cells and CD95⁺GL-7⁺ germinal center (GC) B cells in draining lymph nodes. In addition, curcumin treatment in mice induced total Ab production as well as high affinity IgG1 and IgG2b Ab production. Collectively, these results suggest that curcumin has positive regulatory roles in T(FH) cell functions and GC responses. Thus, this could be an advantageous supplement to enhance humoral immunity against infectious diseases and cancer.


Subject(s)
Animals , Antibody Formation , B-Lymphocytes , Communicable Diseases , Curcuma , Curcumin , Germinal Center , Immunity, Humoral , Immunization , Immunoglobulin G , Immunoglobulins , Lymph Nodes , Lymphoma , Macrophages , Mice , T-Lymphocytes
11.
Article in English | WPRIM | ID: wpr-758951

ABSTRACT

Porcine epidemic diarrhea (PED) is a highly contagious enteric swine disease. The large economic impact of PED on the swine industry worldwide has made the development of an effective PED vaccine a necessity. S0, a truncated region of the porcine epidemic diarrhea virus (PEDV) spike protein, has been suggested as a candidate antigen for PED subunit vaccines; however, poor solubility problems when the protein is expressed in Escherichia coli, and the inherent problems of subunit vaccines, such as low immunogenicity, remain. Flagellin has been widely used as a fusion partner to enhance the immunogenicity and solubility of many difficult-to-express proteins; however, the conjugation effect of flagellin varies depending on the target antigen or the position of the fusion placement. Here, we conjugated flagellin, Vibrio vulnificus FlaB, to the N- and C-termini of S0 and evaluated the ability of the fusion to enhance the solubility and immunogenicity of S0. Flagellin conjugation in the presence of the trigger factor chaperone tig greatly improved the solubility of the fusion protein (up to 99%) regardless of its conjugation position. Of importance, flagellin conjugated to the N-terminus of S0 significantly enhanced S0-specific humoral immune responses compared to other recombinant antigens in Balb/c mice. The mechanism of this phenomenon was investigated through in vitro and in vivo studies. These findings provide important information for the development of a novel PED vaccine and flagellin-based immunotherapeutics.


Subject(s)
Animals , Diarrhea , Escherichia coli , Flagellin , Immunity, Humoral , In Vitro Techniques , Mice , Porcine epidemic diarrhea virus , Solubility , Swine , Swine Diseases , Vaccines, Subunit , Vibrio vulnificus , Vibrio
12.
Neuroscience Bulletin ; (6): 507-518, 2019.
Article in English | WPRIM | ID: wpr-775416

ABSTRACT

Myasthenia gravis (MG) is a prototypical antibody-mediated neurological autoimmune disease with the involvement of humoral immune responses in its pathogenesis. T follicular helper (Tfh) cells have been implicated in many autoimmune diseases. However, whether and how Tfh cells are involved in MG remain unclear. Here, we established and studied a widely-used and approved animal model of human MG, the rat model with acetylcholine receptor alpha (AChRα) subunit (R-AChR)-induced experimental autoimmune myasthenia gravis (EAMG). This model presented mild body-weight loss 10 days after the first immunization (representing the early stage of disease) and more obvious clinical manifestations and body-weight loss 7 days after the second immunization (representing the late stage of disease). AChR-specific pre-Tfh cells and mature Tfh cells were detected in these two stages, respectively. In co-cultures of Tfh cells and B cells, the number of IgG2b-secreting B cells and the level of anti-AChR antibodies in the supernatant were higher in the cultures containing EAMG-derived Tfh cells. In immunohistochemistry and immunofluorescence assays, a substantial number of CD4/Bcl-6 T cells and a greater number of larger germinal centers were observed in lymph node tissues resected from EAMG rats. Based on these results, we hypothesize that an AChR-specific Tfh cell-mediated humoral immune response contributes to the development of EAMG.


Subject(s)
Animals , B-Lymphocytes , Allergy and Immunology , Disease Models, Animal , Female , Immunity, Humoral , Lymph Nodes , Allergy and Immunology , Myasthenia Gravis, Autoimmune, Experimental , Allergy and Immunology , Protein Subunits , Allergy and Immunology , Proto-Oncogene Proteins c-bcl-6 , Allergy and Immunology , Rats, Inbred Lew , Receptor Cross-Talk , Receptors, Cholinergic , Allergy and Immunology , T-Lymphocytes, Helper-Inducer , Allergy and Immunology
13.
Article in English | WPRIM | ID: wpr-773387

ABSTRACT

OBJECTIVE@#This study aimed to characterize the diagnostic and vaccine potential of a novel Mycobacterium tuberculosis antigen Rv0674.@*METHODS@#To evaluate the diagnostic potential and antigenicity of Rv0674, IgG was evaluated using ELISA and interferon (IFN)-γ was done by using ELISpot assay among TB patients and healthy donors. For immunogenicity evaluation, BALB/c mice were immunized with Rv0674. Cytokine production was determined by cytokine release assay using an ELISA kit, and the antibodies were tested using ELISA.@*RESULTS@#The results of serum Elisa tests showed that Rv0674 specific immunoglobulin G (IgG) response was higher in TB patients than negative controls. And Rv0674 had good performance in serological test with sensitivity and specificity of 77.1% and 81.1%, respectively. While it shows poor sensitivity and specificity of 26.23% and 79.69% for IFN-γ tests. In BALB/c mice, Rv0674 adjuvant by DDA/Poly I:C could also induce a high level of IFN-γ, interleukin-2 and interleukin-6 as well as a high IgG titer in both high- and low-dose groups indicating that Rv0674 is essential in humoral and cellular immunity. Moreover, the cytokine profile and IgG isotype characterized Rv0674 as a Th1/Th2-mixed-type protective immunity with the predominance of Th1 cytokines.@*CONCLUSION@#Rv0674 may be a good potential candidate for the development of TB serological diagnosis and a new TB vaccine.


Subject(s)
Adult , Aged , Animals , Antigens, Bacterial , Allergy and Immunology , Female , Humans , Immunity, Cellular , Immunity, Humoral , Male , Mice , Mice, Inbred BALB C , Middle Aged , Tuberculosis , Diagnosis , Allergy and Immunology , Young Adult
14.
Article in English | WPRIM | ID: wpr-773375

ABSTRACT

OBJECTIVE@#To evaluate the effect of intranasal immunization with CTA1-DD as mucosal adjuvant combined with H3N2 split vaccine.@*METHODS@#Mice were immunized intranasally with PBS (negative control), or H3N2 split vaccine (3 μg/mouse) alone, or CTA1-DD (5 μg/mouse) alone, or H3N2 split vaccine (3 μg/mouse) plus CTA1-DD (5 μg/mouse). Positive control mice were immunized intramuscularly with H3N2 split vaccine (3 μg/mouse) and alum adjuvant. All the mice were immunized twice, two weeks apart. Then sera and mucosal lavages were collected. The specific HI titers, IgM, IgG, IgA, and IgG subtypes were examined by ELISA. IFN-γ and IL-4 were test by ELISpot. In addition, two weeks after the last immunization, surivival after H3N2 virus lethal challenge was measured.@*RESULTS@#H3N2 split vaccine formulated with CTA1-DD could elicit higher IgM, IgG and hemagglutination inhibition titers in sera. Furthermore, using CTA1-DD as adjuvant significantly improved mucosal secretory IgA titers in bronchoalveolar lavages and vaginal lavages. Meanwhile this mucosal adjuvant could enhance Th-1-type responses and induce protective hemagglutination inhibition titers. Notably, the addition of CTA1-DD to split vaccine provided 100% protection against lethal infection by the H3N2 virus.@*CONCLUSION@#CTA1-DD could promote mucosal, humoral and cell-mediated immune responses, which supports the further development of CTA1-DD as a mucosal adjuvant for mucosal vaccines.


Subject(s)
Adjuvants, Immunologic , Administration, Intranasal , Animals , Cholera Toxin , Female , Immunity, Humoral , Influenza A Virus, H3N2 Subtype , Allergy and Immunology , Influenza Vaccines , Mice, Inbred BALB C , Nasal Mucosa , Allergy and Immunology , Random Allocation , Recombinant Fusion Proteins
15.
Biol. Res ; 52: 9, 2019. tab, graf
Article in English | LILACS | ID: biblio-1011411

ABSTRACT

BACKGROUND: Fava beans (FBs) have long been used as food, and their principal disadvantage is derived from their haemotoxicity. We hypothesized that FB ingestion alters the intestinal gene expression pattern, thereby inducing an immune response. RESULTS: In-depth sequence analysis identified 769 differentially expressed genes (DEGs) associated with the intestine in FB-treated DBA/1 mouse intestines. The identified genes were shown to be associated with biological processes (such as response to stimulus and immune system processes), human disease pathways (such as infectious diseases, endocrine and metabolic diseases, and immune diseases), and organismal system pathways (such as the digestive system, endocrine system, environmental adaptation, and immune system). Moreover, plasma total immunoglobulin E (IgE), histamine, interleukin (IL)-4 and IL-13 levels were significantly increased when the mice were treated with FBs. CONCLUSIONS: These results demonstrated that FBs affect the intestinal immune response and IgE and cytokine secretion in DBA/1 mice.


Subject(s)
Animals , Male , Mice , Vicia faba/adverse effects , Immunity, Humoral/immunology , Intestinal Mucosa/immunology , Signal Transduction , Reverse Transcriptase Polymerase Chain Reaction , Gene Expression Profiling , Vicia faba/immunology , Favism/etiology , Mice, Inbred DBA
16.
Article in English | WPRIM | ID: wpr-764572

ABSTRACT

OBJECTIVE: Persistent infection of HPV increases the chance of carcinoma in situ of cervix through stages of cervical intraepithelial neoplasia (CIN) 1, 2, and 3, and finally progresses into cervical cancer. We aimed to explore the safety and efficacy of BLS-M07 which is orally administered agent expressing human papillomavirus (HPV) 16 E7 antigen on the surface of Lactobacillus casei in patients with CIN 3. METHODS: Patients with CIN 3 were recruited in our clinical trial. Reid Colposcopic Index (RCI) grading and serum HPV16 E7 specific antibody production were used to evaluate efficacy of BLS-M07. In phase 1, BLS-M07 was administered orally, 5 times a week, on weeks 1, 2, 4, and 8 with dosages of 500 mg, 1,000 mg, and 1,500 mg. In phase 2a, patients were treated with 1,000 mg. The primary endpoints were the safety and the pathologic regression on colposcopic biopsy. RESULTS: Nineteen patients were enrolled in the CIN 3 cohort. In phase 1, no patients experienced dose limiting toxicity. No grade 3 or 4 treatment-related adverse events or deaths were observed. At 16 weeks after treatment, RCI grading was improved and serum HPV16 E7 specific antibody production increased (p<0.05). Six of 8 (75%) patients with CIN 3 were cured in phase 2a. CONCLUSIONS: Oral immunization with BLS-M07 increases production of serum HPV16 E7 specific antibody which induces protective humoral immunity. The safety of this oral vaccine was proved and could be a competitive non-surgical therapeutic agent of CIN 3. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02195089


Subject(s)
Antibody Formation , Biopsy , Carcinoma in Situ , Cervical Intraepithelial Neoplasia , Cervix Uteri , Cohort Studies , Female , Humans , Immunity, Humoral , Immunization , Lactobacillus casei , Papillomavirus E7 Proteins , Papillomavirus Vaccines , Uterine Cervical Neoplasms
17.
Rev. bras. parasitol. vet ; 27(3): 295-300, July-Sept. 2018. graf
Article in English | LILACS | ID: biblio-959190

ABSTRACT

Abstract Twenty-six newborn lambs were evaluated for 21 weeks, from birth to slaughter, to assess their plasma anti-Oestrus ovis immunoglobulin (IgG) using the ELISA technique. On the last day of sampling, all the lambs were slaughtered and O. ovis larvae were recovered, quantified and identified according to the larval stage. High levels of IgG were observed over the first three weeks of life, thus indicating that antibodies are transferred via colostrum from ewes to lambs. Afterwards, the antibody levels declined progressively until the lambs were 11 weeks of age and subsequently started to increase again when they were around 13 weeks of age, reaching the apex on the last week of sampling. All the lambs were parasitized with different larval stages of O. ovis, with an average of 39 larvae per lamb, and the intensity of the infestation ranged from 10 to 97 larvae. However, there was non-significant correlation coefficients between IgG levels and O. ovis larval burden (P > 0.05). In conclusion, although the lambs became infested with O. ovis at an early age, the larval burden was not associated with specific IgG levels.


Resumo Vinte e seis cordeiros recém-nascidos foram avaliados por 21 semanas, desde o nascimento até o abate, para avaliar os níveis plasmáticos de imunoglobulina (IgG) anti-Oestrus ovis utilizando-se a técnica de ELISA. No último dia de coleta, todos os cordeiros foram abatidos e as larvas de O. ovis foram recuperadas, quantificadas e identificadas de acordo com o estádio larval. Foram observados altos níveis de IgG nas primeiras três semanas de vida, indicando que os anticorpos são transferidos por meio do colostro das ovelhas para os cordeiros. Posteriormente, os níveis de anticorpos diminuíram progressivamente, até os cordeiros completarem 11 semanas de vida. Os níveis de IgG começaram a aumentar novamente a partir de 13 semanas de idade, atingindo o ápice na última semana de coleta. Todos os cordeiros estavam parasitados com diferentes estádios larvais de O. ovis com uma média de 39 larvas por cordeiro, e a intensidade da infestação variou de 10 a 97 larvas. Porém, não houve correlação significativa entre os níveis de IgG e a carga larval de O. ovis (P > 0,05). Em conclusão, embora os cordeiros tenham sido infestados com O. ovis ainda jovens, a carga larval não foi associada a níveis específicos de IgG.


Subject(s)
Animals , Sheep Diseases/immunology , Immunoglobulin G/immunology , Sheep/parasitology , Diptera/physiology , Ectoparasitic Infestations/veterinary , Immunity, Humoral/immunology , Sheep Diseases/parasitology , Enzyme-Linked Immunosorbent Assay , Diptera/classification , Ectoparasitic Infestations/immunology , Larva , Animals, Newborn
18.
Rev. bras. parasitol. vet ; 27(2): 191-202, Apr.-June 2018. tab, graf
Article in English | LILACS | ID: biblio-959181

ABSTRACT

Abstract Vaccination against Anaplasma marginale has been considered an important control strategy for bovine anaplasmosis. Recently, mice immunized with rMSP1 a linked to carbon nanotubes (MWNT) showed significant immune responses, generating a new possibility for use of an inactivated vaccine. The objective of this study was to investigate the cellular and humoral responses in calves immunized with MWNT+rMSP1a , associated with inactivated vaccine of A. marginale produced in vitro, and evaluate the toxic effects of the MWNT on renal and hepatic function. rMSP1a was covalently linked to MWNT. Inactivated vaccine (AmUFMG2) was produced by cultivating A. marginale in IDE8 cells. Twenty-four Holstein calves were divided (four groups) and immunized subcutaneously with PBS and non-carboxylated MWNT (control, G1), AmUFMG2 (G2), MWNT+rMSP1a (G3), and AmUFMG2 with MWNT+rMSP1a (G4). Blood samples were collected for total leukocyte counts, biochemical profiling and evaluation of the cellular and humoral response. Immunization with MWNT+rMSP1a induced increase in the total number of leukocytes, NK cells, in the lymphocyte populations and higher levels of antibodies compared to calves immunized only with AmUFMG2. Furthermore, MWNT did not induce changes in the biochemical profile. These data indicate that MWNT+rMSP1a were able to induce the immune responses more efficiently than AmUFMG2 alone, without generating toxicity.


Resumo Vacinação contra Anaplasma marginale tem sido considerada uma importante estratégia de controle da anaplasmose bovina. Recentemente, camundongos imunizados com rMSP1a funcionalizada à nanotubos de carbono (MWNT) apresentaram resposta imune significante, gerando nova possibilidade para o uso da vacina inativada. O objetivo desse estudo foi investigar a resposta celular e humoral em bezerros imunizados com MWNT+rMSP1a, associado com a vacina inativada de A. marginale produzida in vitro, e avaliar os efeitos tóxicos dos MWNT nas funções hepática e renal. rMSP1 a foi ligada covalentemente aos MWNT. Vacina inativada (AmUFMG2) foi produzida através do cultivo de A. marginale em células IDE8. Vinte e quatro bezerros Holandeses foram divididos (quatro grupos) e imunizados subcutaneamente com: PBS e MWNT não-carboxilados (controle, G1), AmUFMG2 (G2), MWNT+rMSP1 a (G3), e AmUFMG2 com MWNT+rMSP1a (G4). Amostras de sangue foram coletadas para contagem de leucócitos, perfil bioquímico e avaliação da resposta celular e humoral. Imunização com MWNT+rMSP1a induziu aumento dos leucócitos totais, células NK, na população de linfócitos e altos níveis de anticorpos comparado com animais imunizados apenas com AmUFMG2. Além disso, MWNT não induziu alterações no perfil bioquímico. Esses dados indicam que MWNT+rMSP1a foram capazes de induzir eficientemente a resposta imune comparado com AmUFMG2 sozinho, sem gerar toxicidade.


Subject(s)
Animals , Cattle , Drug Carriers , Bacterial Vaccines/immunology , Cattle Diseases/microbiology , Cattle Diseases/prevention & control , Nanotubes, Carbon , Anaplasma marginale/immunology , Immunogenicity, Vaccine , Anaplasmosis/prevention & control , Immunity, Humoral , Immunity, Cellular
19.
Braz. j. infect. dis ; 22(1): 41-46, Jan.-feb. 2018. tab, graf
Article in English | LILACS | ID: biblio-951623

ABSTRACT

ABSTRACT Introduction: Immune response to vaccination in infants born prematurely may be lower than in infants born at full-term. Some clinical factors might be associated with humoral immune response. Objectives: The objectives of this study were to compare the immune response to measles and varicella vaccination in infants born prematurely with those born at full-term and to analyze factors associated with measles and varicella antibody levels. Methods: Prospective study including two groups of infants aged 12 months. One group of infants born prematurely with birth-weight <1500 g and who were in follow-up at the outpatient clinic for preterm infants at the institution and other group of infants born at full-term. Infants with malformations, primary immunodeficiency diseases, born to HIV-positive mothers or who had received plasma or immunoglobulin transfusions five months before or three weeks after vaccination were excluded. Plasma antibodies were measured by ELISA and factors associated with antibody levels were assessed by linear regression. Results: Sixty-five premature and 56 full-term infants were included. The percentage of immune individuals after vaccination against measles (100% vs. 100%) and varicella (92.5% vs. 93.2%) were similar in both groups, as well as the antibody levels against measles (2.393 vs. 2.412 UI/mL; p = 0.970) and varicella (0.551 vs. 0.399 UI/mL; p = 0.114). Use of antenatal corticosteroids decreased measles antibody levels whereas breastfeeding for more than six months increased varicella antibody levels. Conclusions: Humoral responses to measles and varicella were similar between infants born prematurely and full-term infants. Measles antibody levels were negatively associated with antenatal corticosteroid use; varicella antibodies were positively associated with prolonged breastfeeding.


Subject(s)
Humans , Male , Female , Infant , Infant, Premature/immunology , Infant, Very Low Birth Weight/immunology , Chickenpox Vaccine/immunology , Measles-Mumps-Rubella Vaccine/immunology , Immunity, Humoral/immunology , Breast Feeding , Enzyme-Linked Immunosorbent Assay , Linear Models , Chickenpox/immunology , Chickenpox/prevention & control , Prospective Studies , Gestational Age , Vaccination/methods , Statistics, Nonparametric , Measles/immunology , Measles/prevention & control , Antibodies, Viral/blood
20.
Article in English | WPRIM | ID: wpr-758865

ABSTRACT

The bursa of Fabricius (BF) is a central humoral immune organ unique to birds. Four bursal peptides (BP-I, BP-II, BP-III, and BP-IV) have been isolated and identified from the BF. In this study, the immunoadjuvant activities of BPs I to IV were examined in mice immunized with H9N2 avian influenza virus (AIV) vaccine. The results suggested that BP-I effectively enhanced cell-mediated immune responses, increased the secretion of Th1 (interferon gamma)- and Th2 (interleukin-4)-type cytokines, and induced an improved cytotoxic T-lymphocyte (CTL) response to the H9N2 virus. BP-II mainly elevated specific antibody production, especially neutralizing antibodies, and increased Th1- and Th2-type cytokine secretion. BP-III had no significant effect on antibody production or cell-mediated immune responses compared to those in the control group. A strong immune response at both the humoral and cellular levels was induced by BP-IV. Furthermore, a virus challenge experiment followed by H&E staining revealed that BP-I and BP-II promoted removal of the virus and conferred protection in mouse lungs. BP-IV significantly reduced viral titers and histopathological changes and contributed to protection against H9N2 AIV challenge in mouse lungs. This study further elucidated the immunoadjuvant activities of BPs I to IV, providing a novel insight into immunoadjuvants for use in vaccine design.


Subject(s)
Adjuvants, Immunologic , Animals , Antibodies, Neutralizing , Antibody Formation , Birds , Bursa of Fabricius , Cytokines , Immunity, Cellular , Immunity, Humoral , Influenza A Virus, H9N2 Subtype , Influenza in Birds , Lung , Mice , Peptides , T-Lymphocytes, Cytotoxic
SELECTION OF CITATIONS
SEARCH DETAIL